DANVERS, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the U.S. Food and Drug Administration (FDA) approval of a prospective feasibility study to evaluate the use of the Impella CP heart pump for unloading of the left ventricle prior to primary percutaneous coronary intervention (PCI) in patients presenting with ST segment elevation myocardial infarction (STEMI), without cardiogenic shock. This trial will focus on feasibility and safety, and lay the groundwork for a future trial, designed to measure the impact that unloading may have on infarct size related to reperfusion injury, an acceleration of myocardial damage at the time of revascularization, in STEMI patients.
Impella® heart pumps are not currently approved for use in STEMI patients without cardiogenic shock. The STEMI patient segment is contributing to the growing heart failure population and represents a potential new patient indication that may benefit from Impella pump unloading the left ventricle.
STEMI is a type of heart attack caused by a blockage in one of the main heart arteries, preventing the flow of oxygen to the heart. It is estimated that 965,000 people a year have heart attacks1, of which approximately 200,000 are classified as STEMI2. The current standard of care is called Door to Balloon “DTB”, for the angioplasty balloon. The recommended treatment in guidelines for STEMI is revascularization (opening the blocked artery) to restore oxygen supply to the heart muscle through primary PCI within 90 minutes or less from the time of first medical contact. Despite current guidelines, 76% of patients experiencing their first acute myocardial infarction (AMI), will develop heart failure within five years3. Additionally, within five years of a patient surviving their first heart attack, 36% of men and 47% of women will die due to heart failure1. It is estimated that the number of heart failure patients will grow to 8 million people by 2030 with enormous associated costs4. Survival from heart attacks has been improved by the successful DTB protocol; however, this treatment is speculated to be contributing to the growing epidemic of heart failure.
The study, “Door to Unloading (DTU) with Impella CP System in Acute Myocardial Infarction to Reduce Infarct Size,” is a prospective, multi-center feasibility study led by principal investigators Dr. Navin K. Kapur of Tufts Medical Center and Dr. William W. O’Neill of Henry Ford Medical Center. Up to 50 patients at 10 sites will be included in the study, which is expected to initiate in the first half of calendar 2017 and be completed within 18 months.
The primary endpoint of the study will assess infarct size as percent of left ventricular mass at 30 days post-PCI using a cardiac magnetic resonance (CMR) imaging technique. Patients will be randomized to Impella CP placement with immediate primary PCI, or to Impella CP placement with 30 minutes of unloading prior to primary PCI. This feasibility study is designed to evaluate safety and the protocol and not sized to show significant statistical difference.
“As clinicians and scientists, we appreciate the FDA's approval of this feasibility study,” said Dr. Navin Kapur, “And we are excited to further investigate whether mechanically reducing the workload of the heart before reopening a blocked coronary artery reduces myocardial damage and the subsequent development of heart failure.”
“The majority of patients with large myocardial infarction involving the front wall of the heart develop congestive heart failure within five years,” said Dr. William W. O’Neill. “The process of reperfusion with primary PCI should be investigated with new therapeutic strategies targeting myocardial reperfusion injury, which may improve clinical outcomes for patients.”
The study hypothesis, based on extensive mechanistic research, is that unloading the left ventricle prior to PCI reduces myocardial work load, oxygen demand and initiate a cardioprotective effect which attenuates myocardial damage caused by reperfusion injury at the time of revascularization.
“Abiomed is committed to investing in innovative research to improve patient outcomes. We believe that reducing heart muscle injury is the key to recovering hearts, avoiding heart failure, improving patient quality of life and reducing health care costs,” said Michael R. Minogue, Abiomed President, Chairman and Chief Executive Officer.
The Impella CP is a percutaneous catheter-based blood pump that can be placed across the aortic valve into the left ventricle using a single femoral or axillary arterial access to support systemic circulation. The device pumps blood from the left ventricle into the ascending aorta at an average flow rate of 3.5 L/min.
The Impella products offer the unique ability to stabilize the patient's hemodynamics and unload the heart, which allows the muscle to rest and potentially recover its native function. Impella 2.5 received FDA PMA approval for high risk PCI in March 2015. Impella 2.5, Impella CP, and Impella 5.0 received FDA PMA approval for cardiogenic shock in the setting of acute myocardial infarction/heart attack or after heart surgery. These are the first and only percutaneous temporary ventricular support devices that are FDA-approved as safe and effective for the cardiogenic shock indication. The Impella product portfolio, which is comprised of Impella 2.5, Impella CP, Impella 5.0, Impella LD, and Impella RP, has supported over 40,000 patients in the United States.
The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella 2.5, Impella 5.0, Impella LD, and Protected PCI are trademarks of Abiomed, Inc.
Abiomed, Inc. based in Danvers, Massachusetts, is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.